SCR-LIP-000706 · Claim · machine-readable JSON →

Morphological lipedema stage correlates poorly with symptom burden and lymphatic function, so it may not be a valid measure of severity.

General proposition consolidated from 5 earlier single-paper claims; each study's own result is shown as its finding.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
moderate (GRADE)
Evidence
5 source(s)
Dates
2026-11-20 → 2026-11-20

Structured evidence, machine-compiled — not a verdict.

Evidence over time

20182025Hallazgos linfogammagráficos en pacientes con lipedema — Forner-Cordero et al. (2018) · consistentIndocyanine green lymphography as novel tool to assess lymphatics in patients with lipedema — Buso et al. (2021) · consistentS2k guideline lipedema — Faerber et al. (2024) · consistentObservational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History — Patton et al. (2024) · conflictingClinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025) · consistent

Evidence (5)

Context (PECO)

PopulationSwiss women with lipedema, types I–V, stages 1–4
Conditionlipedema
Exposureadvanced morphological stage (staging 1–4)
Comparatorlower lipedema stages
Outcomesymptom burden (HADS, BPI, FSS, SF-36 scores)
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Change log